Kinases as targets for anti-diabetic therapy
AssigneeMax-Planck-Gesellschaft zur Forderung der Wissenschaften e.V.
InventorsMathias Falcenberg, Axel Ullrich
Life of this patent
Estimating the term…
Abstract
The present invention is related to compound capable of modulating the activity and/or expression of the protein kinases SCYL1, ADCK1, and GRK5, thereby enhancing the expression and/or release of insulin. The invention is further related to methods of identifying said compounds for the treatment of diseases of the carbohydrate metabolism. The invention is further related to methods of treatment of diseases of the carbohydrate metabolism, particularly diabetes mellitus type 2.
Claims14
A modulator for
- a) inhibition of at least one of the protein kinases selected from the group consisting of SCYL1, ADCK1, and GRK5 or
- b) inactivation, degradation, downregulation, intercalation of at least one nucleic acid selected from the group consisting of the nucleic acid encoding SCYL1, the nucleic acid encoding ADCK1, and the nucleic acid encoding GRK5,
- for the treatment of a disease of the carbohydrate metabolism.
A method for screening for a modulator for treatment of a disease of the carbohydrate metabolism, the method comprising
- a) contacting a test compound with at least one polypeptide selected from the group consisting of SCYL1, ADCK1, and GRK5 polypeptide,
- b) detecting the binding of said test compound to the SCYL1, ADCK1, or GRK5 polypeptide, and
- c) determining the activity of the SCYL1, ADCK1, or GRK5 polypeptide in the presence of said test compound.
A kit comprising
- a) SCYL1, ADCK1, and/or GRK5 polypeptides,
- b) a nucleic acid encoding SCYL1, a nucleic acid encoding ADCK1, and a nucleic acid encoding GRK5,
- c) a cell line with insulin production,
- d) a control compound known to affect the insulin production by binding the SCYL1, ADCK1, and/or GRK5 polypeptide or the corresponding nucleic acid.
A method for treatment of a metabolic disease comprising:
- administering a subject in need thereof a therapeutically effective amount of at least one modulator for:
- a) inhibition or activation of at least one of the tyrosine kinases selected from the group consisting of SCYL1, ADCK1, and GRK5, or
- b) inactivation, degradation, downregulation, intercalation or activation of at least one nucleic acid selected from the group consisting of the nucleic acid encoding SCYL1, the nucleic acid encoding ADCK1, and the nucleic acid encoding GRK5.
Dependencies are inferred from the claim text.